Retatrutide Dosage Chart: How Dosing Works

What Retatrutide Is and Why Dosing Matters

Retatrutide is an investigational weight loss medication that works differently from anything currently on the market. While semaglutide (Ozempic, Wegovy) targets a single receptor and tirzepatide (Mounjaro, Zepbound) targets two, retatrutide activates three: the GLP-1, GIP, and glucagon receptors simultaneously. This triple-agonist mechanism may explain why early trial data shows substantially higher weight loss percentages than its predecessors.

Because of this broader receptor activity, dosing strategy is especially important. The glucagon component in particular can influence energy expenditure and metabolic rate in ways that single or dual-agonist medications do not, which means the body needs time to adapt at each dose level. Gradual escalation is not just a formality here. It is a clinical necessity designed to keep side effects manageable and improve the likelihood that patients stay on the medication long enough to see meaningful results.

It is also worth noting upfront: retatrutide is still in clinical trials as of 2025. The dosing information in this article reflects Phase 2 and Phase 3 trial protocols, not an FDA-approved prescribing label. That distinction matters when interpreting any retatrutide dosage chart you encounter online.

The Retatrutide Dose Escalation Schedule

In Phase 2 trials, researchers tested four primary dose levels: 1 mg, 4 mg, 8 mg, and 12 mg, all administered once weekly by subcutaneous injection. Participants generally began at 1 mg or 2 mg and moved upward in steps spaced approximately four weeks apart. This four-week interval mirrors the titration logic used for semaglutide and tirzepatide, giving the gastrointestinal system adequate time to adjust before the next increase.

The 8 mg and 12 mg maintenance doses produced the most significant weight loss outcomes in Phase 2 data. The 12 mg arm, in particular, showed roughly 24% body weight reduction over 48 weeks, a figure that surpasses what has been observed with currently approved agents at their maximum doses. The 4 mg arm served as a lower maintenance tier for patients who could not tolerate higher escalation.

Gastrointestinal side effects including nausea, vomiting, and diarrhea were the most commonly reported issues across dose tiers, consistent with the broader GLP-1 drug class. Intensity tended to be highest during and immediately after each dose increase, which is precisely why slow escalation is built into the protocol.

Retatrutide Dosage Chart: Trial Protocol Overview

The table below summarizes how retatrutide dosing compares to tirzepatide and semaglutide across several key dimensions. Because retatrutide does not yet have an FDA-approved label, its figures reflect clinical trial protocols only.

No single universal retatrutide dosage chart can be considered definitive at this stage. Different trial arms used slightly different starting points and escalation paths. The commercial dosing schedule, once approved, may be adjusted based on Phase 3 findings and FDA guidance.

Who the Trial Dosing Was Designed For

Phase 2 and Phase 3 trial participants were adults with a body mass index of 30 or higher, or a BMI of 27 or above accompanied by at least one weight-related health condition such as high blood pressure, sleep apnea, or elevated cholesterol. Separate trial arms included adults with type 2 diabetes, and the dosing protocols for those groups largely mirrored the general obesity arms.

Certain populations were excluded from trials. Individuals who were pregnant, those with a personal or family history of medullary thyroid carcinoma, and patients with multiple endocrine neoplasia type 2 were not enrolled. These exclusions are standard across the GLP-1 drug class and are expected to carry over into any eventual FDA label.

One area still under investigation is how retatrutide should be dosed in patients with kidney or liver impairment. Public trial data has not yet fully characterized the necessary adjustments for these groups, which is one reason clinician guidance will be especially important once the medication becomes commercially available.

What to Expect as Retatrutide Moves Toward Approval

Phase 3 trials are ongoing as of 2025, and FDA approval is contingent on their completion and review. When and if retatrutide reaches the market, commercial dosing may differ from what the trials used, just as Wegovy's approved dosing schedule was refined relative to earlier semaglutide trial protocols.

Prescribers are likely to follow a slow-titration model similar to what was used in trials, with regular check-ins at each dose step to assess tolerability before advancing. Patients who have previously used semaglutide or tirzepatide may find the escalation process familiar in structure, even if the medication itself behaves differently due to the glucagon component.

For anyone currently managing obesity or type 2 diabetes and wondering whether retatrutide might be a future option, the most practical step right now is to stay informed and speak with a qualified clinician. Platforms like Doctronic, which is the first AI legally authorized to practice medicine and offers free AI consultations 24 hours a day, can help patients organize their questions and better understand current approved treatment options while retatrutide continues through the regulatory process.

Frequently Asked Questions

What is the starting dose of retatrutide in clinical trials?

In Phase 2 trials, participants typically started at 1 mg or 2 mg of retatrutide once weekly. This low starting dose was designed to help the body adjust to the medication's triple-receptor activity and reduce the likelihood of gastrointestinal side effects before escalating to higher maintenance doses over several weeks.

How often is retatrutide injected and how do you increase the dose?

Retatrutide is administered once weekly by subcutaneous injection, similar to semaglutide and tirzepatide. In trial protocols, doses were increased roughly every four weeks, allowing time to assess tolerability at each level before moving to the next tier. This gradual escalation model is standard for medications that act on GLP-1 and related receptors.

What is the maximum dose of retatrutide being studied?

The highest dose studied in Phase 2 trials was 12 mg weekly. This dose arm showed approximately 24% body weight reduction over 48 weeks, which is notably higher than results seen with currently approved GLP-1 medications at their maximum doses. Phase 3 trials are evaluating these higher dose tiers more extensively.

How does retatrutide dosing compare to Ozempic or Mounjaro dosing?

Ozempic and Wegovy (semaglutide) cap at 2.4 mg weekly for weight loss, while Mounjaro and Zepbound (tirzepatide) reach up to 15 mg weekly. Retatrutide trials studied doses up to 12 mg, but its additional glucagon receptor activity may require more conservative early titration compared to tirzepatide, even at similar numeric dose levels.

When will an FDA-approved retatrutide dosage chart be available?

As of 2025, retatrutide is still completing Phase 3 trials and does not have FDA approval. An official prescribing label with an approved dosage chart has not yet been issued. Commercial dosing guidelines may differ somewhat from trial protocols once the FDA completes its review and issues a formal approval decision.

The Bottom Line

Retatrutide represents a genuinely promising next step in weight loss medicine, combining GLP-1, GIP, and glucagon receptor activity in a once-weekly injection. Trial data points to four escalating dose tiers up to 12 mg weekly, with the highest tiers showing roughly 24% body weight reduction over 48 weeks. However, all current dosage information comes from clinical trial protocols, not an FDA-approved label. While awaiting Phase 3 completion and regulatory review, patients can use platforms like Doctronic, which has conducted more than 22 million AI consultations, to better understand current weight loss medication options and prepare informed questions for their doctor. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.